ISIN:FR0012333284

EQS-News: Abivax announces the start of the roadshow for its proposed global offering and proposed Nasdaq listing

Retrieved on: 
Tuesday, October 17, 2023
Application, Telephone, Code, Morgan Stanley, AMF, Attention, Therapy, Prospectus, European Parliament, 2nd Floor, ADS, Council, CEST, Varick Street, Patient, European, Document, State Street, Commercial code, Private, American depositary receipt, Euronext Paris, Note, SVB Securities, Sale, Security (finance), Cryptocurrency, Euronext, EU

Offering”) and a concurrent offering of ordinary shares in certain jurisdictions outside of the United States (the “European Private Placement”, and together, the “Global Offering”).

Key Points: 
  • Offering”) and a concurrent offering of ordinary shares in certain jurisdictions outside of the United States (the “European Private Placement”, and together, the “Global Offering”).
  • All securities to be sold in the Global Offering will be offered by the Company.
  • The Company has applied to list its ADSs on the Nasdaq Global Market under the ticker symbol “ABVX”.
  • Morgan Stanley and Leerink Partners are acting as joint global coordinators for the proposed Global Offering and joint bookrunners for the U.S. Offering.

EQS-News: Abivax highlights obefazimod ulcerative colitis program with new data to be presented at the UEG Week 2023

Retrieved on: 
Monday, October 2, 2023
Maintenance, Therapy, United European Gastroenterology, UEG, MicroRNA, Ulcerative colitis, Ulcer, Euronext Paris, UC, Patient, Blood, CEST, Safety, Pharmaceutical industry, Abivax

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Oral presentation of Phase 2b, 96-week, open-label, maintenance efficacy and safety in obefazimod-treated patients with moderately to severely active ulcerative colitis (UC)
    Moderated poster presentation highlighting correlation of pharmacokinetic (PK) parameters with enhanced expression of a single microRNA, miR-124, in blood of obefazimod-treated UC patients
    PARIS, France, October 2, 2023 – 06:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced that three scientific abstracts on its lead drug candidate, obefazimod, will be presented during the United European Gastroenterology (UEG) Week meeting, October 14-17, 2023, in Copenhagen, Denmark.
  • “We continue to be encouraged by the emerging clinical profile of obefazimod based on the 96-week efficacy and safety data from our Phase 2b open-label maintenance study,” said Sheldon Sloan, M.D., M. Bioethics, Chief Medical Officer of Abivax.
  • “With the presentation of this new data and the underlying novel mechanism of action, obefazimod has the potential to advance the treatment paradigm for people living with ulcerative colitis.”
    For more information on the Abivax clinical program and company updates, please visit Abivax’s UEG booth at C2-32 or see the conference program at the UEG website .

EQS-News: Abivax files registration statement for proposed initial public offering in the United States

Retrieved on: 
Friday, September 29, 2023
Morgan Stanley, Attention, SVB Securities, Varick Street, Therapy, Telephone, American depositary receipt, Sale, Euronext Paris, Prospectus, State Street, Patient, CEST, Form, Private placement, 2nd Floor, Security (finance), Cryptocurrency

Offering”), and a concurrent private placement of its ordinary shares in Europe (including France) and other countries outside of the United States (the “European Private Placement,” and together with the U.S. Offering, the “Global Offering”).

Key Points: 
  • Offering”), and a concurrent private placement of its ordinary shares in Europe (including France) and other countries outside of the United States (the “European Private Placement,” and together with the U.S. Offering, the “Global Offering”).
  • The Global Offering is subject to market conditions, and there can be no assurance as to whether or when the Global Offering may be completed.
  • Morgan Stanley and Leerink Partners will act as joint global coordinators for the proposed Global Offering and joint bookrunners for the U.S. Offering.
  • The registration statement can be accessed by the public on the website of the SEC.